Beyond Therapeutics

Beyond Therapeutics (BeyondTX) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule drugs for the treatment of cancer. Founded by the scientific leadership team from Turning Point Therapeutics, the company leverages a proprietary structure-based drug design platform to create highly selective and potent inhibitors for challenging oncogenic targets. Its lead candidate, BTX-A, is a first-in-class small molecule inhibitor of B7-H3 (CD276), an immune checkpoint protein overexpressed in various solid tumors. Beyond Therapeutics aims to overcome the limitations of current therapies by targeting intracellular and extracellular protein domains with precision. The company is headquartered in San Diego, California, and is backed by prominent life science investors including OrbiMed and F-Prime Capital.